Germany’s DAX top-30 index was set to open 0.1 percent lower on Monday, according to premarket data from brokerage Lang & Schwarz, in response to the fact that activity in China’s factory sector edged up to a seven-month high in February but export orders shrank and deflationary pressures persisted, a private business survey showed, adding to the view that yet more interest rate cuts will be needed.
Insights about those healthcare sector stocks that declined during Friday’s trade in U.S. stock exchange, are depicted underneath:
Biocept, Inc. (NASDAQ:BIOC)’s shares dwindled -9.71%, and closed at $3.16, during the last trading session, soon after a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests, declared that the Company will issue its financial results for the fourth quarter of 2014 on Monday, March 9, 2015, after the close of the market, and will hold a conference call on this day at 4:30 p.m. ET to talk about the financial results and provide a company update.
Biocept, Inc. (NASDAQ:BIOC), headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment.
Tandem Diabetes Care Inc (NASDAQ:TNDM), declined -4.41%, and closed at $11.70, soon after a medical device company, declared that Kim Blickenstaff, president and CEO, will present a company update at the Cowen and Company 35th Annual Health Care Conference in Boston, MA. The presentation will take place on Tuesday, March 3, 2015 at 9:20am Eastern Time (6:20am Pacific Time).
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin.
Insulet Corporation (NASDAQ:PODD), dipped -3.59%, and closed at $31.73, after the news release that the development, manufacturing and sale of its OmniPod Insulin Administration System, declared financial results for the three months and full year ended December 31, 2014.
Fourth Quarter Highlights and Recent Developments:
- Ongoing to drive OmniPod adoption resulting in double digit year-over-year growth.
- Strengthening senior leadership team with key executive appointments in commercial operations counting sales, marketing, managed care and customer support.
- Forming drug delivery business unit with the addition of practiced senior executives.
- Extending exclusive blood glucose meter partnership with Abbott Laboratories.
- Transforming Canadian distribution to a direct model for OmniPod.
“Insulet’s OmniPod System, the leading tubeless insulin delivery technology and most differentiated insulin delivery system on the market, allows us to further our leadership in ‘intelligent’ drug delivery,” said Patrick Sullivan, President and Chief Executive Officer. “We have recently improved our senior administration team with several executives who bring outstanding experience and executional expertise to Insulet and together we are driving focus, growth and raised accountability throughout the entire organization. We are confident that we have the right strategy and team to take Insulet to the next level and ensure OmniPod remains well-positioned for continued adoption in the U.S. and international markets.”
Insulet Corporation (NASDAQ:PODD), is engaged in the development, manufacturing and sale of its OmniPod Insulin Administration System (the OmniPod System). The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a disposable tubeless OmniPod which is worn on the body for about three days at a time and the Company’s handheld, wireless Personal Diabetes Manager (PDM).
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), dropped -5.25%, and closed at $4.87, soon after the news release that a clinical-stage biotechnology company, declared that Vincent Milano, Idera’s Chief Executive Officer presented a corporate update at the 2015 RBC Capital Markets’ Global Healthcare Conference on Wednesday February 25, 2015 at 9:00 a.m. Eastern Time at the New York Palace Hotel.
Mr. Milano will also be presenting at the Cowen and Company 35th Annual Healthcare Conference on Monday, March 2, 2015 at 4:50 p.m. Eastern Time at the Boston Marriott Copley Place.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare diseases. Idera’s proprietary technology involves using a Toll-like receptor (TLR) targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs.
